Testing for coronavirus
Syndromic testing

The future of infectious disease diagnostics

Patients with infectious illnesses often have signs and symptoms that are indicative of a disease, but that isn't specific enough to clinically distinguish what makes them ill. These patients are frequently given broad treatment, heavy monitoring and possibly unnecessary interventions. This puts a burden on healthcare systems, clinical labs and clinicians, and means patients aren't getting the best care possible.

We’re committed to helping healthcare workers like you navigate the challenges of diagnosing infectious diseases. That’s why we’ve developed an easy-to-use, automated diagnostic testing system that can help eliminate the guesswork and make your job easier. Our tests use multiplex PCR technology – also known as syndromic testing – that can quickly survey many different pathogens in a single patient sample. With syndromic testing, you get the answers you need, when you need them. And your patients get better care, faster.
Meet the challenges this respiratory season will bring

The arrival of the influenza-like illness season has coincided with another rise in COVID-19 cases, as the pandemic continues across the globe. Syndromic testing can simplify the diagnosis of respiratory diseases and help facilitate fast clinical decision making.

This respiratory season will be uniquely challenging
Visit our respiratory resources hub to learn how we can support you.
Dr. Celestin Alexis Agbessi
“It changed our perception, our prescription habits, and it will change the way we work in the future. In the end, we gain money for both the community and the patients. That is really a big step forward.”

Celestin Alexis Agbessi, M.D., Bichat-Claude Bernard Hospital, Paris

Great Lakes Labs president and CEO Michelle Volk
“It’s hugely beneficial to be able to test for that wide range of pathogens. Ruling out COVID is helpful, but so is the chance to correctly identify other illnesses so physicians can treat the patients and their symptoms appropriately.”

Michelle Volk, CEO and president of Great Lakes Labs, Indiana, USA

Joshua Arant
“Our value to our patients and to our provider community has increased by bringing the QIAstat-Dx in-house.”

Joshua Arant, Founder and Chief Operations Officer, Mako Medical

New to rapid diagnostics with syndromic testing?
Find the information you need and learn how to incorporate syndromic testing into your diagnostic strategy.
  1. Yalamanchili H, et al. (2018) Gastroenterol Hepatol, 14(11):646-652
  2. Binnicker M. Multiplex. (2015) J. Clin Microbiology, 53(12):3723-3728
  3. Macfarlane-Smith L, et al. (2018) Gastrointestinal Infections, 34(1):19-2
  4. Echavarria M, et al. (2018) J Clin Virol, 108:90–95
  5. Beal S G, et al. (2018) J Clin Microbiol, 18;56(1)
  6. Bouzid D, et al. (2020) J Hospital Infection, 337-338
  7. Iroh Tam PY, et al. (2017) Children (Basel), 4(1)
  8. Zhu et al. (2018) Clin Pediatr, 58(2): 185-190
  9. Martinez RM, et al. (2016) Clinical Virology Symposium, Poster #C-368

The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
  • This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.